ATE419252T1 - Antagonisten des a2b-adenosinrezeptors - Google Patents
Antagonisten des a2b-adenosinrezeptorsInfo
- Publication number
- ATE419252T1 ATE419252T1 AT04810023T AT04810023T ATE419252T1 AT E419252 T1 ATE419252 T1 AT E419252T1 AT 04810023 T AT04810023 T AT 04810023T AT 04810023 T AT04810023 T AT 04810023T AT E419252 T1 ATE419252 T1 AT E419252T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- optionally substituted
- disorders
- sub
- substituted heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51601903P | 2003-10-31 | 2003-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE419252T1 true ATE419252T1 (de) | 2009-01-15 |
Family
ID=34549473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04810023T ATE419252T1 (de) | 2003-10-31 | 2004-10-26 | Antagonisten des a2b-adenosinrezeptors |
Country Status (13)
Country | Link |
---|---|
US (1) | US7449473B2 (de) |
EP (1) | EP1678181B1 (de) |
JP (1) | JP4863876B2 (de) |
KR (1) | KR20060111467A (de) |
CN (1) | CN1890241A (de) |
AT (1) | ATE419252T1 (de) |
AU (1) | AU2004285013A1 (de) |
BR (1) | BRPI0415888A (de) |
CA (1) | CA2544193C (de) |
DE (1) | DE602004018808D1 (de) |
ES (1) | ES2318363T3 (de) |
MX (1) | MXPA06004789A (de) |
WO (1) | WO2005042534A2 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
ES2387653T3 (es) * | 2004-09-01 | 2012-09-27 | Gilead Sciences, Inc. | Procedimiento de cicatrización de heridas utilizando antagonistas del receptor de adenosina A2B |
NZ589657A (en) | 2004-10-15 | 2012-06-29 | Gilead Palo Alto Inc | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
CA2612344A1 (en) * | 2005-06-16 | 2006-12-28 | Cv Therapeutics, Inc. | Prodrugs of a2b adenosine receptor antagonists |
ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
CA2644996A1 (en) * | 2006-03-02 | 2007-09-13 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
US20090124640A1 (en) * | 2006-06-05 | 2009-05-14 | Astrazeneca Ab | Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor |
TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
US7470697B2 (en) * | 2006-09-01 | 2008-12-30 | Adenosine Therapeutics, Llc | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors |
GB0718434D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
GB0718432D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
TW200938200A (en) * | 2007-12-28 | 2009-09-16 | Dainippon Sumitomo Pharma Co | Methyl-substituted piperidine derivative |
CN102015712A (zh) | 2008-03-26 | 2011-04-13 | 阿德维纳斯治疗私人有限公司 | 作为腺苷受体拮抗剂的杂环化合物 |
US20110118276A1 (en) * | 2008-07-16 | 2011-05-19 | Edward Leung | Methods of treating atherosclerosis |
DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
BRPI1009398A2 (pt) | 2009-03-13 | 2016-03-08 | Advinus Therapeutics Private Ltd | compostos de pirimidina fundida substituída |
WO2011055391A1 (en) | 2009-11-09 | 2011-05-12 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
EP2571882A1 (de) * | 2010-05-21 | 2013-03-27 | Gilead Sciences, Inc. | Hetercyclische flaviviridae-virenhemmer |
US8940751B2 (en) | 2010-09-13 | 2015-01-27 | Advinus Therapeutics Private Limited | Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications |
WO2013101598A1 (en) * | 2011-12-27 | 2013-07-04 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
WO2015003881A1 (en) * | 2013-07-08 | 2015-01-15 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
WO2016023831A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives |
BR112021012685A2 (pt) | 2019-01-11 | 2021-12-28 | Omeros Corp | Métodos para tratar câncer, para aumentar o nível de citocinas th1 nas células mononucleares de sangue periférico humanas, para realçar uma resposta imune antitumoral e para estimular e/ou amplificar uma resposta imune em um sujeito mamífero sofrendo de ou em risco de desenvolver câncer ou metástase de câncer, e, composição farmacêutica |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1254915B (it) * | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
DE19535504A1 (de) | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
WO2001094350A1 (en) | 2000-06-07 | 2001-12-13 | Almirall Prodesfarma S.A. | 6-phenylpyrrolopyrimidinedione derivatives |
ES2193839B1 (es) * | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
WO2003006465A1 (en) * | 2001-07-13 | 2003-01-23 | Cv Therapeutics, Inc. | Partial and full agonist of a adenosine receptors |
US7157440B2 (en) * | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
NZ532816A (en) * | 2001-11-09 | 2005-11-25 | Cv Therapeutics Inc | A2B adenosine receptor antagonists |
-
2004
- 2004-10-26 CA CA2544193A patent/CA2544193C/en active Active
- 2004-10-26 BR BRPI0415888-1A patent/BRPI0415888A/pt not_active Application Discontinuation
- 2004-10-26 WO PCT/US2004/035453 patent/WO2005042534A2/en active Application Filing
- 2004-10-26 US US10/973,167 patent/US7449473B2/en active Active
- 2004-10-26 JP JP2006538172A patent/JP4863876B2/ja active Active
- 2004-10-26 MX MXPA06004789A patent/MXPA06004789A/es unknown
- 2004-10-26 KR KR1020067008426A patent/KR20060111467A/ko not_active Application Discontinuation
- 2004-10-26 DE DE602004018808T patent/DE602004018808D1/de active Active
- 2004-10-26 AT AT04810023T patent/ATE419252T1/de not_active IP Right Cessation
- 2004-10-26 AU AU2004285013A patent/AU2004285013A1/en not_active Abandoned
- 2004-10-26 EP EP04810023A patent/EP1678181B1/de active Active
- 2004-10-26 ES ES04810023T patent/ES2318363T3/es active Active
- 2004-10-26 CN CNA200480031969XA patent/CN1890241A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2007509947A (ja) | 2007-04-19 |
BRPI0415888A (pt) | 2007-01-09 |
ES2318363T3 (es) | 2009-05-01 |
EP1678181A2 (de) | 2006-07-12 |
EP1678181B1 (de) | 2008-12-31 |
US7449473B2 (en) | 2008-11-11 |
CA2544193C (en) | 2012-03-27 |
WO2005042534A2 (en) | 2005-05-12 |
WO2005042534A3 (en) | 2005-08-25 |
DE602004018808D1 (de) | 2009-02-12 |
CN1890241A (zh) | 2007-01-03 |
MXPA06004789A (es) | 2006-07-03 |
KR20060111467A (ko) | 2006-10-27 |
US20050119287A1 (en) | 2005-06-02 |
JP4863876B2 (ja) | 2012-01-25 |
CA2544193A1 (en) | 2005-05-12 |
AU2004285013A1 (en) | 2005-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE419252T1 (de) | Antagonisten des a2b-adenosinrezeptors | |
ATE520694T1 (de) | A2b-adenosinrezeptorantagonisten | |
EP2370429B1 (de) | P38-map-kinase-inhibitoren | |
ES2237843T3 (es) | Nuevos compuestos de imidazol sustituidos. | |
WO2010038085A2 (en) | P38 mapk kinase inhibitor | |
JP2005531584A5 (de) | ||
JP2006514110A (ja) | Ip受容体アンタゴニストとしてのフェニルまたはヘテロアリールアミノアルカン誘導体 | |
WO2010038086A2 (en) | Novel compounds | |
WO2009029998A1 (en) | Retrometabolic compounds | |
JP2004107299A (ja) | 新規1−置換ウラシル誘導体及びアレルギー性疾患の治療剤 | |
CA2540163A1 (en) | Thrombin receptor antagonists | |
JP2004217668A (ja) | インダゾール誘導体、およびホスホジエステラーゼ(pde)タイプivと腫瘍壊死因子(tnf)産生の阻害剤としてのインダゾール誘導体の使用 | |
EP2556068A1 (de) | P38-map-kinasehemmer | |
JP2008543860A5 (de) | ||
CA2712367C (en) | Sulphoximine-substituted quinazoline derivatives as immunomodulators, their preparation and use as medicaments | |
JP2007509947A5 (de) | ||
WO2005035501A1 (ja) | 新規オレフィン誘導体 | |
ES2291630T3 (es) | Nuevos compuestos. | |
WO2006016237A3 (en) | Heterocyclic derivatives as anti-inflammatory agents | |
JPH01313469A (ja) | キナゾリン、その製法及びこれを含有する抗腫瘍作用を有する製薬学的組成物 | |
WO2008071665A1 (en) | A nicotinamide derivative useful as p38 kinase inhibitor | |
TH85135B (th) | ตัวยับยั้งเบนซาไมด์ของ p2x 7 รีเซพเตอร์ | |
TH87151A (th) | สารประกอบเคมี |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |